CNST Stock Surges on Analyst Note

The brokerage bunch was already optimistic coming into today

by Lillian Currens

Published on Feb 13, 2020 at 12:29 PM

Constellation Pharmaceuticals Inc (NASDAQ:CNST) is bucking the broad-market trend today, and surging after SunTrust Robinson initiated coverage with a "buy" rating and a $50 price target -- a roughly 43% premium to last night's close. The analyst said Constellation's myelofibrosis drug candidate CPI-1610 showed promised, calling it "likely ahead of the competition." The stock is up 7.1% to trade at $37.24, and is on track for its highest close in two weeks. 

Plus, CNST is looking to overtake its 20-day moving average, which has acted as a ceiling on the charts this year, leading the equity lower. The stock is still eyeing a nearly 20% year-to-date drop, but boasts a 224.6% gain in the last 12 months of trading. 

CNST Chart Feb 13

While options activity is still running at a relatively low volume, the 165 calls that have crossed the tape represent 27 times the expected intraday volume. It looks like most of this activity surrounds the September 45 call, where positions are possibly being sold to open, suggesting these traders are calling the $45 level as a ceiling for CNST ahead of the contracts expiration on Sept. 18. The 25-strike put from the same series is also getting some attention, with positions being opened here. 

Circling back to analyst sentiment, it looks like those in coverage are pretty optimistic. Coming into today, the stock sported seven "buy" or better ratings, and just one "hold." Meanwhile, this penchant for bullish bets in the options pits also seems to be the norm, with 7.6 calls bought for every put at the the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX). 

Keeping all this in mind, options look like an attractive way to bet on Constellation Pharmaceuticals next move. The equity's Schaeffer's Volatility Index (SVI) of 76% sits lower than all other readings from the past year, suggesting options haven't priced in such low volatility expectations in the past 12 months. 


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.
Cannabis Stock Rally Cut Short after Downgrade
Aurora Cannabis did receive a price-target hike from Jefferies, though
Vaccines, China Trigger Roller Coaster Week for Stocks
Moderna's vaccine captured the attention of Wall Street
Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.